Skip to main content

Advertisement

SpringerLink
Log in

Aspirin Use in Women: Current Perspectives and Future Directions

  • Women and Ischemic Heart Disease (E. Jackson, Section Editor)
  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

This review examines the recent literature on the use of low-dose aspirin (LDA) for primary and secondary prevention of cardiovascular disease in women, use of LDA for pre-eclampsia prevention in pregnancy, and the underutilization of aspirin therapy in women as compared to men.

Recent Findings

While men and women should not differ with respect to aspirin use for secondary prevention, its role in primary prevention remains unclear for both sexes, with particular uncertainty in women. Reflective of this are conflicting recommendations in current guidelines for primary prevention and thus investigations of primary prevention aspirin use are ongoing and will play an important role in elucidating its efficacy. While there is significant heterogeneity in studies to date of LDA for pre-eclampsia prevention, based on recent meta-analyses suggesting promising results, guidelines now recommend initiation in high risk women after the 12th week of gestation. Finally, studies consistently reveal that aspirin therapy is underutilized in women as compared to men, suggesting a need to better educate physicians and the general public about its use in women.

Summary

Further research is needed to better elucidate the role of aspirin in women for primary prevention of cardiovascular disease and for pre-eclampsia in high risk pregnant women. In addition, further investigation into the factors that lead to the current underutilization of aspirin in women are required in order to ensure that patients of both sexes are optimally treated, with the goal of improving cardiovascular outcomes in all patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Becker DM, Segal J, Vaidya D, Yanek LR, Herrera-Galeano JE, Bray PF, et al. Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA. 2006;295:1420–7.

    Article  CAS  PubMed  Google Scholar 

  2. Shen H, Herzog W, Drolet M, Pakyz R, Newcomer S, Sack P, et al. Aspirin resistance in healthy drug-naive men versus women (from the Heredity and Phenotype Intervention Heart Study). Am J Cardiol. 2009;104:606–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88:230–5.

    Article  CAS  PubMed  Google Scholar 

  4. Qayyum R, Becker DM, Yanek LR, Moy TF, Becker LC, Faraday N, et al. Platelet inhibition by aspirin 81 and 325 mg/day in men versus women without clinically apparent cardiovascular disease. Am J Cardiol. 2008;101:1359–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. •• Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293–304. The Women’s Health Study remains the largest randomized trial of primary prevention aspirin in women to date.

    Article  CAS  PubMed  Google Scholar 

  6. Cook NR, Cole SR, Buring JE. Aspirin in the primary prevention of cardiovascular disease in the Women’s Health Study: effect of noncompliance. Eur J Epidemiol. 2012;27:431–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. van Kruijsdijk RC, Visseren FL, Ridker PM, Dorresteijn JA, Buring JE, van der Graaf Y, et al. Individualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy women. Heart. 2015;101:369–76.

    Article  PubMed  Google Scholar 

  8. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012;13:518–27.

    Article  CAS  PubMed  Google Scholar 

  9. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295:306–13.

    Article  CAS  PubMed  Google Scholar 

  10. Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–60.

  11. Guirguis-Blake JM, Evans CV, Senger CA, O’Connor EA, Whitlock EP. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. preventive services task force. Ann Intern Med. 2016;164:804–13.

    Article  PubMed  Google Scholar 

  12. • Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women—2011 update: a guideline from the American heart association. Circulation. 2011;123:1243–62. Updated National Guidelines on Prevention of Cardiovascular Disease in Women.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Int J Behav Med. 2012;19:403–88.

    Article  PubMed  Google Scholar 

  14. United States Food and Drug Administration. Use of Aspirin for Primary Prevention of Heart Attack and Stroke. 2014. http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm390574.htm.

  15. Bibbins-Domingo K, U.S. Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. preventive services task force recommendation statement. Ann Intern Med. 2016;164:836–45.

  16. ASPREE Investigator Group. Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. Contemp Clin Trials. 2013;36:555–64.

  17. De Berardis G, Sacco M, Evangelista V, Filippi A, Giorda CB, Tognoni G, et al. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials. 2007;8:21.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Aung T, Haynes R, Barton J, Cox J, Murawska A, Murphy K et al. Cost-effect recruitment methods for a large randomised trial in people with diabetes: A Study of Cardiovascular Events iN Diabetes (ASCEND). Trials. 2016;17(1). doi:10.1186/s13063-016-1354-9.

  19. A study to assess the efficacy and safety of enteric-coated acetylsalicylic acid in patients at moderate risk of cardiovascular disease (ARRIVE). ClinicalTrials.gov Identifier NCT00501059. 2016. https://clinicaltrials.gov/ct2/show/NCT00501059.

  20. Mora S. Aspirin therapy in women: back to the ABCs. Circ Cardiovasc Qual Outcomes. 2009;2:63–4.

    Article  PubMed  Google Scholar 

  21. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1998;2:349–60.

  22. Berger JS, Brown DL, Burke GL, Oberman A, Kostis JB, Langer RD, et al. Aspirin use, dose, and clinical outcomes in postmenopausal women with stable cardiovascular disease: the Women’s Health Initiative Observational Study. Circ Cardiovasc Qual Outcomes. 2009;2:78–87.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Mehta SR, Bassand JP, Chrolavicious S, Diaz R, Eikelboom JW et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010;363:930–42.

  24. Rivera CM, Song J, Copeland L, Buirge C, Ory M, McNeal CJ. Underuse of aspirin for primary and secondary prevention of cardiovascular disease events in women. J Women’s Health. 2012;21:379–87.

    Article  Google Scholar 

  25. Cannon CP, Rhee KE, Califf RM, Boden WE, Hirsch AT, Alberts MJ, et al. Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). Am J Cardiol. 2010;105:445–52.

    Article  CAS  PubMed  Google Scholar 

  26. Fang J, George MG, Gindi RM, Hong Y, Yang Q, Ayala C, et al. Use of low-dose aspirin as secondary prevention of atherosclerotic cardiovascular disease in US adults (from the National Health Interview Survey, 2012). Am J Cardiol. 2015;115:895–900.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Luepker RV, Steffen LM, Duval S, Zantek ND, Zhou X, Hirsch AT. Population trends in aspirin use for cardiovascular disease prevention 1980–2009: The Minnesota Heart Survey. J Am Heart Assoc. 2015;4.

  28. Greving JP, Buskens E, Koffijberg H, Algra A. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. Circulation. 2008;117:2875–83.

    Article  PubMed  Google Scholar 

  29. Ananth CV, Keyes KM, Wapner RJ. Pre-eclampsia rates in the United States, 1980–2010: age-period-cohort analysis. BMJ. 2013;347:f6564.

    Article  PubMed  PubMed Central  Google Scholar 

  30. • LeFevre ML, U.S. Preventive Services Task Force. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;161:819–26. National recommendations on aspirin use for women at risk for preeclampsia.

  31. Lisonkova S, Sabr Y, Mayer C, Young C, Skoll A, Joseph KS. Maternal morbidity associated with early-onset and late-onset preeclampsia. Obstet Gynecol. 2014;124:771–81.

    Article  PubMed  Google Scholar 

  32. Henderson JT, O’Connor E, Whitlock EP. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia. Ann Intern Med. 2014;161:613–4.

    Article  PubMed  Google Scholar 

  33. Schaap TP, Knight M, Zwart JJ, Kurinczuk JJ, Brocklehurst P, van Roosmalen J, et al. Eclampsia, a comparison within the International Network of Obstetric Survey Systems. BJOG. 2014;121:1521–8.

    Article  CAS  PubMed  Google Scholar 

  34. Gold RA, Gold KR, Schilling MF, Modilevsky T. Effect of age, parity, and race on the incidence of pregnancy associated hypertension and eclampsia in the United States. Pregnancy Hypertens. 2014;4:46–53.

    PubMed  Google Scholar 

  35. Katsi V, Kanellopoulou T, Makris T, Nihoyannopoulos P, Nomikou E, Tousoulis D. Aspirin vs heparin for the prevention of preeclampsia. Curr Hypertens Rep. 2016;18:57.

    Article  PubMed  Google Scholar 

  36. Slone D, Siskind V, Heinonen OP, Monson RR, Kaufman DW, Shapiro S. Aspirin and congenital malformations. Lancet. 1976;1:1373–5.

    Article  CAS  PubMed  Google Scholar 

  37. Werler MM, Mitchell AA, Shapiro S. The relation of aspirin use during the first trimester of pregnancy to congenital cardiac defects. N Engl J Med. 1989;321:1639–42.

    Article  CAS  PubMed  Google Scholar 

  38. Di Sessa TG, Moretti ML, Khoury A, Pulliam DA, Arheart KL, Sibai BM. Cardiac function in fetuses and newborns exposed to low-dose aspirin during pregnancy. Am J Obstet Gynecol. 1994;171:892–900.

    Article  PubMed  Google Scholar 

  39. Wyatt-Ashmead J. Antenatal closure of the ductus arteriosus and hydrops fetalis. Pediatr Dev Pathol: Off J Soc Pediatr Pathol Paediatr Pathol Soc. 2011;14:469–74.

    Article  Google Scholar 

  40. Henderson JT, Whitlock EP, O’Conner E, Senger CA, Thompson JH, Rowland MG. Low-dose aspirin for the prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the US preventive services task force. Rockville (MD)2014.

  41. World Health Organization. WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. 2011. http://apps.who.int/iris/bitstream/10665/44703/1/9789241548335_eng.pdf.

  42. Henderson JT, Whitlock EP, O’Connor E, Senger CA, Thompson JH, Rowland MG. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2014;160:695–703.

    Article  PubMed  Google Scholar 

  43. American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122:1122–31.

  44. Werner EF, Hauspurg AK, Rouse DJ. A cost-benefit analysis of low-dose aspirin prophylaxis for the prevention of preeclampsia in the United States. Obstet Gynecol. 2015;126:1242–50.

    Article  CAS  PubMed  Google Scholar 

  45. American Congress of Obstetricians and Gynecologists. Practice advisory on low-dose aspirin and prevention of preeclampsia: updated recommendations. 2016. http://www.acog.org/About-ACOG/News-Room/Practice-Advisories/Practice-Advisory-Low-Dose-Aspirin-and-Prevention-of-Preeclampsia-Updated-Recommendations.

  46. • Xu TT, Zhou F, Deng CY, Huang GQ, Li JK, Wang XD. Low-dose aspirin for preventing preeclampsia and its complications: a meta-analysis. J Clin Hypertens. 2015;17:567–73. A recent meta-analysis examining 29 randomized controlled trials of low dose aspirin for pre-eclampsia prevention, which revealed a reduction in the incidence of pre-eclampsia, with greatest efficacy prior to 16 weeks of gestation.

    Article  CAS  Google Scholar 

  47. • Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol. 2010;116:402–14. A meta-analysis of 34 randomized controlled trials of low dose aspirin, which revealed that initiation of low dose aspirin at 16 weeks of gestation or earlier yielded a significant reduction in the incidence of pre-eclampsia, whereas initiation after 16 weeks of gestation did not.

    Article  PubMed  Google Scholar 

  48. O’Gorman N, Wright D, Rolnik DL, Nicolaides KH, Poon LC. Study protocol for the randomised controlled trial: combined multimarker screening and randomised patient treatment with ASpirin for evidence-based PREeclampsia prevention (ASPRE). BMJ Open. 2016;6, e011801.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Mone F, Mulcahy C, McParland P, Stanton A, Culliton M, Downey P, et al. An open-label randomized-controlled trial of low dose aspirin with an early screening test for pre-eclampsia and growth restriction (TEST): Trial protocol. Contemp Clin Trials. 2016.

  50. Caron N, Rivard GE, Michon N, Morin F, Pilon D, Moutquin JM, et al. Low-dose ASA response using the PFA-100 in women with high-risk pregnancy. JOGC. 2009;31:1022–7.

    PubMed  Google Scholar 

  51. Rey E, Rivard GE. Is testing for aspirin response worthwhile in high-risk pregnancy? Eur J Obstet Gynecol Reprod Biol. 2011;157:38–42.

    Article  PubMed  Google Scholar 

  52. Mannisto T, Mendola P, Vaarasmaki M, Jarvelin MR, Hartikainen AL, Pouta A, et al. Elevated blood pressure in pregnancy and subsequent chronic disease risk. Circulation. 2013;127:681–90.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Black MH, Zhou H, Sacks DA, Dublin S, Lawrence JM, Harrison TN, et al. Hypertensive disorders first identified in pregnancy increase risk for incident prehypertension and hypertension in the year after delivery. J Hypertens. 2016;34:728–35.

    Article  CAS  PubMed  Google Scholar 

  54. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007;335:974.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Wikstrom AK, Haglund B, Olovsson M, Lindeberg SN. The risk of maternal ischaemic heart disease after gestational hypertensive disease. BJOG. 2005;112:1486–91.

    Article  PubMed  Google Scholar 

  56. Lykke JA, Langhoff-Roos J, Sibai BM, Funai EF, Triche EW, Paidas MJ. Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. Hypertension. 2009;53:944–51.

    Article  CAS  PubMed  Google Scholar 

  57. Cao Y, Nishihara R, Wu K, Wang M, Ogino S, Willett WC, et al. Population-wide impact of long-term use of aspirin and the risk for cancer. JAMA Oncol. 2016;2:762–9.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Bardia A, Keenan TE, Ebbert JO, Lazovich D, Wang AH, Vierkant RA, et al. Personalizing aspirin use for targeted breast cancer chemoprevention in postmenopausal women. Mayo Clin Proc. 2016;91:71–80.

    Article  CAS  PubMed  Google Scholar 

  59. Friel G, Liu CS, Kolomeyevskaya NV, Hampras SS, Kruszka B, Schmitt K, et al. Aspirin and acetaminophen use and the risk of cervical cancer. J Low Genit Tract Dis. 2015;19:189–93.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, USA

    Amy Sarma & Nandita S. Scott

Authors
  1. Amy Sarma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nandita S. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nandita S. Scott.

Ethics declarations

Conflict of Interest

Amy Sarma and Nandita S. Scott declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Women and Ischemic Heart Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sarma, A., Scott, N.S. Aspirin Use in Women: Current Perspectives and Future Directions. Curr Atheroscler Rep 18, 74 (2016). https://doi.org/10.1007/s11883-016-0630-1

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11883-016-0630-1

Keywords

Search

Navigation